Synapse - OncoKB: A precision oncology knowledge base

OncoKB: A precision oncology knowledge base Journal Article

Authors:	Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; Chang, M. T.; Chandarlapaty, S.; Traina, T. A.; Paik, P. K.; Ho, A. L.; Hantash, F. M.; Grupe, A.; Baxi, S. S.; Callahan, M. K.; Snyder, A.; Chi, P.; Danila, D. C.; Gounder, M.; Harding, J. J.; Hellmann, M. D.; Iyer, G.; Janjigian, Y. Y.; Kaley, T.; Levine, D. A.; Lowery, M.; Omuro, A.; Postow, M. A.; Rathkopf, D.; Shoushtari, A. N.; Shukla, N.; Voss, M. H.; Paraiso, E.; Zehir, A.; Berger, M. F.; Taylor, B. S.; Saltz, L. B.; Riely, G. J.; Ladanyi, M.; Hyman, D. M.; Baselga, J.; Sabbatini, P.; Solit, D. B.; Schultz, N.
Article Title:	OncoKB: A precision oncology knowledge base
Abstract:	Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format.Tothis end,we developed OncoKB, an expert-guided precision oncology knowledge base. Methods OncoKB annotates the biologic and oncogenic effects and prognostic and predictive significance of somatic molecular alterations. Potential treatment implications are stratified by the level of evidence that a specific molecular alteration is predictive of drug responseonthe basis of US Food and Drug Administration labeling, National Comprehensive Cancer Network guidelines, disease-focused expert group recommendations, and scientific literature. Results To date, > 3,000 unique mutations, fusions, and copy number alterations in 418 cancerassociated genes have been annotated. To test the utility of OncoKB, we annotated all genomic events in 5,983 primary tumor samples in 19 cancer types. Forty-one percent of samples harbored at least one potentially actionable alteration, of which 7.5% were predictive of clinical benefit from a standard treatment. OncoKB annotations are available through a public Web resource (http://oncokb.org) and are incorporated into the cBioPortal for Cancer Genomics to facilitate the interpretation of genomic alterations by physicians and researchers. Conclusion OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions. © 2018 American Society of Clinical Oncology.
Keywords:	gene mutation; somatic mutation; evidence based medicine; medical decision making; internet; food and drug administration; cancer therapy; prediction; cancer genetics; drug response; gene fusion; drug labeling; cancer tissue; factual database; medical expert; personalized medicine; scientific literature; copy number variation; cancer prognosis; human; priority journal; article; oncokb
Journal Title:	JCO Precision Oncology
Volume:	1
ISSN:	2473-4284
Publisher:	American Society of Clinical Oncology
Date Published:	2017-01-01
Language:	English
DOI:	10.1200/po.17.00011
PROVIDER:	scopus
PMCID:	PMC5586540
PUBMED:	28890946
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077486246&doi=10.1200%2fPO.17.00011&partnerID=40&md5=e2ece691a5fcb4a64164e59abaed458a
Notes:	Article -- Export Date: 3 February 2020 -- Source: Scopus